NVNovavax NVAX · NASDAQ
$11.26 -12.17% (-$1.56)
- Market cap
- $2.11B
- Enterprise value
- $2.22B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 5.1x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -36.5%
- Bruto marža
- 77.9%
- Neto marža
- -59.9%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 2.44
- Free float
- 87.6%
O podjetju
Novavax (NVAX) is a biotechnology company focused on developing innovative vaccine technologies. Their main goal is to provide effective and safe vaccinations against infectious diseases. Currently, Novavax is dedicated to the development of a vaccine for respiratory viruses, including COVID-19. Novavax stock is suitable for investors who closely follow the biotechnology industry and seek opportunities in the healthcare sector. Add Novavax stock to your watchlist on Bulios and stay informed about the latest developments and news regarding this innovative biotech company.
Sector
Healthcare
Industry
Biotechnology
CEO
John Charles Jacobs
Employees
749
Headquarters
Gaithersburg
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke